1. Oral phage therapy with microencapsulated phage A221 against Escherichia coli infections in weaned piglets
- Author
-
Xinyu Mao, Yuxing Wu, Runwen Ma, Lei Li, Leping Wang, Yizhou Tan, Ziyong Li, Hui Liu, Kaiou Han, Yajie Cao, Yinan Li, Hao Peng, Xun Li, Chuanhuo Hu, and Xiaoye Wang
- Subjects
Oral ,Microencapsulated phage ,Treatment ,Escherichia coli ,Diarrhea ,Veterinary medicine ,SF600-1100 - Abstract
Abstract Background Escherichia coli (E. coli) is a common pathogen that often causes diarrhea in piglets. Since bacteria are becoming more and more resistant to antibiotics, phages have become a promising alternative therapy. However, the therapy of oral phage often fails to achieve the desired effect. A novel phage named A221 was isolated by using E. coli GXXW-1103 as host strain, characterized by electron microscopy, genomic sequencing and analyzed by measuring lysis ability in vitro. Results Phage A221 was identified as a member of Ackermannviridae, Aglimvirinae, Agtrevirus with 153297 bp genome and effectively inhibited bacterial growth in vitro for 16 h. This study was conducted to evaluate the therapeutic effect of oral microencapsulated phage A221 on E. coli GXXW-1103 infections in weaned piglets. The protective effect of phage was evaluated by body weight analysis, bacterial load and histopathological changes. The results showed that with the treatment of phage A221, the body weight of piglets increased, the percentage of Enterobacteriaceae in duodenum decreased to 0.64%, the lesions in cecum and duodenum were alleviated, and the bacterial load in the jejunal lymph nodes, cecum and spleen were also significantly different with infected group (P
- Published
- 2023
- Full Text
- View/download PDF